CN Patent

CN103664776B — 一种酪氨酸激酶抑制剂及其中间体的制备方法

Assigned to Zhengda Tianqing Guangzhou Pharmaceutical Co ltd · Expires 2016-05-04 · 10y expired

What this patent protects

本发明涉及一种酪氨酸激酶抑制剂及其中间体的制备方法。本发明的方法是以化合物1，1-环丙烷二羧酸二酯为原料，通过两种途径制备得1-((4-((6，7-二甲氧基喹啉-4-基)氧基)苯基)氨甲酰基)环丙烷甲酸酯；经水解后，与对氟苯胺反应，制备得Cabozantinib。本发明涉及的制备方法反应条件温和，操作简便，降低了合成成本，适合工业化生产。

USPTO Abstract

本发明涉及一种酪氨酸激酶抑制剂及其中间体的制备方法。本发明的方法是以化合物1，1-环丙烷二羧酸二酯为原料，通过两种途径制备得1-((4-((6，7-二甲氧基喹啉-4-基)氧基)苯基)氨甲酰基)环丙烷甲酸酯；经水解后，与对氟苯胺反应，制备得Cabozantinib。本发明涉及的制备方法反应条件温和，操作简便，降低了合成成本，适合工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN103664776B
Jurisdiction
CN
Classification
—
Expires
2016-05-04
Drug substance claim
No
Drug product claim
No
Assignee
Zhengda Tianqing Guangzhou Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.